ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Biochanin A enhances wound healing in diabetic rats: emphasis on antioxidant, anti-inflammatory, angiogenic and pro-collagen activities.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic wounds represent a serious complication, affecting ~ 25% of patients and may lead to amputation, with significant socioeconomic consequences. This study investigated the potential of biochanin A (BCA), a natural isoflavone, to enhance wound healing in a diabetic rat model. Diabetes was induced via streptozotocin. A full-thickness about ~ 1-cm dorsal wound was created, and animals were grouped into five groups: non-diabetic control, untreated diabetic, vehicle-treated diabetic, BCA-treated diabetic, and a positive control group. All respective treatments were applied topically once daily for 14 days. Wound closure was monitored periodically. On day 15, rats were sacrificed and tissue samples were collected for histological evaluation, immunohistochemistry, and biochemical analysis to assess oxidative stress, inflammation, angiogenesis marker, and collagen deposition. BCA treatment significantly accelerated wound contraction and improved healing rates compared to untreated diabetic controls. Histopathological examination using hematoxylin and eosin and staining by Masson's trichrome showed enhanced granulation tissue formation, re-epithelialization, and neovascularization. Mechanistically, BCA activated Nrf2 and NAD(P)H:NQO1, upregulated key antioxidant enzymes SOD and CAT, and reduced lipid peroxidation accumulation. It also suppressed immune-expression of pro-inflammatory markers. Furthermore, BCA treatment enhanced expression of critical angiogenic growth factors VEGF-A and PDGFR and enhanced collagen deposition as evidenced by increased immune-expression of TGF-β1 and mRNA expression of Col1A1. Our findings demonstrate that BCA promotes diabetic wound healing through a multi-targeted mechanism involving enhancement of the antioxidant system, attenuation of the inflammatory phase, and stimulation of angiogenesis and collagen deposition.
Indexed as
Identifiers
42247007What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.